FDA to Review Actelion Ltd.'s (JOBS) Zavesca for Additional Use

Bookmark and Share

Reuters -- Actelion Ltd, Europe’s largest biotech company, said on Thursday the U.S. Food and Drug Administration (FDA) would review use of its drug Zavesca to treat a rare neurodegenerative disease early next year.

MORE ON THIS TOPIC